Nifty
Sensex
:
:
15820.00
52772.97
41.55 (0.26%)
119.90 (0.23%)

Pharmaceuticals & Drugs - Global

Rating :
40/99

BSE: 530549 | NSE: SHILPAMED

627.05
29-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  631.65
  •  636.95
  •  622.00
  •  630.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  306931
  •  1923.45
  •  695.00
  •  311.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 5,109.29
  • 34.57
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,454.61
  • 0.18%
  • 3.46

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.25%
  • 8.70%
  • 17.90%
  • FII
  • DII
  • Others
  • 14.56%
  • 2.94%
  • 2.65%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.08
  • 4.85
  • 4.80

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.76
  • 6.04
  • 7.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.23
  • 7.34
  • 11.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.33
  • 27.26
  • 24.01

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.10
  • 3.65
  • 2.55

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.57
  • 20.72
  • 16.61

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
208.03
219.99
-5.44%
191.25
236.85
-19.25%
278.94
289.92
-3.79%
222.87
160.99
38.44%
Expenses
181.82
174.40
4.25%
170.28
163.11
4.40%
210.25
221.91
-5.25%
157.11
132.19
18.85%
EBITDA
26.21
45.60
-42.52%
20.97
73.74
-71.56%
68.68
68.00
1.00%
65.75
28.80
128.30%
EBIDTM
12.60%
20.73%
10.96%
31.13%
24.62%
23.46%
29.50%
17.89%
Other Income
6.91
8.91
-22.45%
8.61
3.25
164.92%
9.20
5.82
58.08%
5.48
1.98
176.77%
Interest
9.12
1.01
802.97%
4.80
1.27
277.95%
3.95
0.82
381.71%
4.00
1.46
173.97%
Depreciation
15.23
11.55
31.86%
13.72
10.97
25.07%
12.70
10.66
19.14%
12.33
10.66
15.67%
PBT
8.76
41.95
-79.12%
11.05
64.76
-82.94%
61.23
62.34
-1.78%
115.74
18.66
520.26%
Tax
0.80
7.55
-89.40%
2.92
10.53
-72.27%
15.99
11.18
43.02%
29.14
4.05
619.51%
PAT
7.97
34.40
-76.83%
8.14
54.24
-84.99%
45.24
51.16
-11.57%
86.60
14.61
492.74%
PATM
3.83%
15.64%
4.25%
22.90%
16.22%
17.65%
38.86%
9.07%
EPS
0.96
4.24
-77.36%
0.94
6.75
-86.07%
5.57
6.23
-10.59%
10.59
1.93
448.70%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
901.09
907.91
733.39
788.83
779.16
716.43
613.80
571.38
371.32
318.18
290.29
Net Sales Growth
-0.73%
23.80%
-7.03%
1.24%
8.76%
16.72%
7.42%
53.88%
16.70%
9.61%
 
Cost Of Goods Sold
270.75
277.73
257.03
355.87
371.81
366.19
323.16
313.26
213.95
183.22
162.98
Gross Profit
630.34
630.18
476.36
432.95
407.36
350.25
290.63
258.12
157.38
134.96
127.31
GP Margin
69.95%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
45.17%
42.38%
42.42%
43.86%
Total Expenditure
719.46
693.39
579.39
637.60
617.55
556.44
487.38
455.40
301.63
257.08
219.70
Power & Fuel Cost
-
38.76
33.57
28.86
26.30
21.90
19.29
17.37
10.67
9.38
7.03
% Of Sales
-
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
3.04%
2.87%
2.95%
2.42%
Employee Cost
-
196.59
176.40
149.35
127.87
90.09
82.30
67.83
42.56
33.68
28.37
% Of Sales
-
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
11.87%
11.46%
10.59%
9.77%
Manufacturing Exp.
-
79.19
61.23
59.96
52.55
45.35
36.55
27.44
16.92
12.89
8.35
% Of Sales
-
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
4.80%
4.56%
4.05%
2.88%
General & Admin Exp.
-
70.26
27.20
22.50
16.95
14.11
10.64
9.53
9.51
7.87
5.64
% Of Sales
-
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
1.67%
2.56%
2.47%
1.94%
Selling & Distn. Exp.
-
10.40
6.72
6.37
4.75
7.27
5.99
7.29
4.43
3.19
4.63
% Of Sales
-
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
1.28%
1.19%
1.00%
1.59%
Miscellaneous Exp.
-
20.47
17.23
14.68
17.32
11.54
9.45
12.68
3.59
6.86
4.63
% Of Sales
-
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
2.22%
0.97%
2.16%
0.93%
EBITDA
181.61
214.52
154.00
151.23
161.61
159.99
126.42
115.98
69.69
61.10
70.59
EBITDA Margin
20.15%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
20.30%
18.77%
19.20%
24.32%
Other Income
30.20
22.22
15.56
32.62
29.34
11.36
6.93
9.12
5.01
8.28
8.95
Interest
21.87
4.56
3.68
2.66
3.13
3.93
4.05
3.52
2.27
2.31
2.63
Depreciation
53.98
43.78
42.06
37.22
30.64
23.14
21.41
23.22
15.34
14.36
12.96
PBT
196.78
188.40
123.82
143.96
157.17
144.28
107.89
98.35
57.10
52.71
63.95
Tax
48.85
33.49
26.18
33.91
42.04
35.62
35.22
20.30
9.53
12.22
14.60
Tax Rate
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
21.27%
16.72%
22.91%
22.83%
PAT
147.95
156.50
120.28
112.43
113.71
109.84
73.69
75.67
47.35
41.23
49.35
PAT before Minority Interest
148.67
154.91
117.52
110.05
110.59
106.24
72.62
75.15
47.47
41.11
49.35
Minority Interest
0.72
1.59
2.76
2.38
3.12
3.60
1.07
0.52
-0.12
0.12
0.00
PAT Margin
16.42%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
13.24%
12.75%
12.96%
17.00%
PAT Growth
-4.18%
30.11%
6.98%
-1.13%
3.52%
49.06%
-2.62%
59.81%
14.84%
-16.45%
 
EPS
18.15
19.20
14.76
13.80
13.95
13.48
9.04
9.28
5.81
5.06
6.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
396.45
320.42
275.98
224.68
Share Capital
8.15
8.15
8.15
8.01
7.71
7.71
7.36
4.90
4.90
4.80
Total Reserves
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
389.09
315.52
271.07
213.85
Non-Current Liabilities
256.94
166.62
153.48
251.26
67.23
154.15
104.53
98.51
31.13
31.85
Secured Loans
164.48
80.39
67.09
141.20
0.03
71.03
37.43
70.47
5.07
11.42
Unsecured Loans
0.53
0.70
1.03
1.30
0.00
31.30
30.05
0.00
0.00
0.00
Long Term Provisions
26.17
21.77
20.32
16.89
13.96
11.75
9.93
6.92
6.34
5.71
Current Liabilities
407.74
253.44
265.84
236.90
222.07
189.06
166.84
123.77
121.14
80.21
Trade Payables
89.46
80.72
103.74
111.86
106.48
75.50
92.98
51.26
56.72
27.90
Other Current Liabilities
142.11
81.62
59.59
28.03
36.49
49.32
38.23
23.38
20.34
16.65
Short Term Borrowings
165.27
86.58
98.12
92.41
74.10
58.47
30.27
45.07
41.24
33.15
Short Term Provisions
10.90
4.52
4.39
4.60
5.00
5.77
5.37
4.06
2.83
2.51
Total Liabilities
1,986.13
1,610.02
1,499.13
1,472.22
930.89
904.54
677.83
551.42
433.11
338.21
Net Block
650.44
558.01
534.20
491.93
393.41
316.06
294.42
180.67
166.61
146.25
Gross Block
986.42
853.16
793.24
704.89
582.20
476.34
448.38
300.89
271.30
232.84
Accumulated Depreciation
335.98
295.15
259.04
212.96
188.79
160.28
153.96
120.22
104.70
86.59
Non Current Assets
1,365.35
1,064.96
827.16
742.33
576.68
576.77
443.89
339.18
244.95
159.79
Capital Work in Progress
666.25
429.12
209.85
140.51
91.90
221.62
111.03
129.15
57.71
2.72
Non Current Investment
10.45
2.25
20.79
27.99
34.15
0.19
0.21
0.14
0.11
3.65
Long Term Loans & Adv.
32.42
48.75
37.47
77.09
51.86
38.74
38.18
28.82
20.17
6.62
Other Non Current Assets
5.78
26.84
24.86
4.80
5.36
0.16
0.06
0.40
0.34
0.00
Current Assets
620.78
545.06
671.97
729.88
354.21
327.61
233.74
211.99
187.87
178.39
Current Investments
0.00
0.00
119.54
224.62
59.63
65.35
10.14
50.28
68.02
0.00
Inventories
226.43
187.67
188.71
190.00
134.23
130.78
123.25
74.33
67.32
43.33
Sundry Debtors
243.72
203.73
220.27
170.93
125.43
81.37
67.96
41.79
40.53
40.13
Cash & Bank
44.56
94.54
73.83
100.39
11.03
18.42
9.19
16.87
2.27
87.20
Other Current Assets
106.06
45.04
26.08
22.00
23.90
31.69
23.20
28.72
9.72
7.72
Short Term Loans & Adv.
29.25
14.08
43.54
21.95
8.90
4.91
3.23
2.86
3.01
1.56
Net Current Assets
213.04
291.62
406.13
492.98
132.14
138.55
66.90
88.22
66.73
98.18
Total Assets
1,986.13
1,610.02
1,499.13
1,472.21
930.89
904.54
677.83
551.42
433.10
338.21

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
123.72
146.78
44.92
37.48
128.70
68.81
70.04
43.64
56.73
40.86
PBT
188.40
143.70
136.77
146.49
140.36
107.84
95.45
57.00
53.51
64.13
Adjustment
41.32
20.44
18.83
17.19
20.61
26.46
19.62
11.52
10.19
10.42
Changes in Working Capital
-63.80
18.71
-69.66
-92.61
-2.70
-40.11
-23.44
-13.90
0.77
-21.04
Cash after chg. in Working capital
165.92
182.85
85.94
71.08
158.27
94.19
91.62
54.62
64.46
53.51
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
-21.58
-10.98
-7.73
-12.61
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-288.85
-196.16
-8.76
-262.23
-109.20
-195.18
-48.93
-95.21
-152.31
7.77
Net Fixed Assets
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
-61.02
-83.52
-79.20
-5.23
Net Investments
-4.44
141.85
95.51
-172.72
-14.09
-64.38
12.08
13.84
-73.05
-24.39
Others
-280.13
-81.05
32.48
82.72
-2.97
-52.34
0.01
-25.53
-0.06
37.39
Cash from Financing Activity
175.50
10.06
-60.91
312.70
-19.65
135.05
-28.34
66.31
10.02
35.93
Net Cash Inflow / Outflow
10.38
-39.32
-24.75
87.95
-0.15
8.68
-7.23
14.74
-85.56
84.56
Opening Cash & Equivalents
34.36
73.83
99.97
7.05
3.61
9.19
16.87
2.27
87.83
2.65
Closing Cash & Equivalent
44.56
34.36
73.83
99.97
6.43
18.42
9.19
16.87
2.27
87.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
163.06
146.89
133.09
123.17
82.91
70.92
107.72
43.52
74.94
60.67
ROA
8.62%
7.56%
7.41%
9.20%
11.58%
9.18%
12.23%
9.64%
10.66%
16.84%
ROE
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
20.98%
15.93%
16.63%
30.96%
ROCE
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
20.48%
15.04%
18.02%
28.98%
Fixed Asset Turnover
0.99
0.89
1.06
1.22
1.36
1.34
1.54
1.32
1.28
1.30
Receivable days
89.94
105.51
90.20
69.00
52.26
43.99
34.62
39.70
45.47
46.24
Inventory Days
83.24
93.66
87.32
75.49
66.97
74.84
62.33
68.31
62.38
57.79
Payable days
46.83
58.00
61.51
60.89
60.10
62.86
57.06
63.94
59.10
55.44
Cash Conversion Cycle
126.35
141.17
116.00
83.61
59.13
55.97
39.90
44.07
48.76
48.59
Total Debt/Equity
0.29
0.16
0.18
0.24
0.14
0.34
0.30
0.41
0.22
0.26
Interest Cover
42.34
40.09
55.10
49.69
37.07
27.63
28.09
26.13
24.13
25.28

News Update:


  • Shilpa Medicare gets nod to transfer API Business to WOS
    13th Jul 2021, 11:29 AM

    The company has received approval from Board of Directors for transfer of API Business of the Company consisting of Unit-1 and Unit-2 situated at Raichur, Karnataka

    Read More
  • Shilpa Medicare gets approval to manufacture, sale of 2-Deoxy-D-Glucose
    25th Jun 2021, 11:14 AM

    2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients

    Read More
  • Shilpa Medicare launches pediatric dose Paracetamol Oral Thin Film
    22nd Jun 2021, 10:59 AM

    The company received approval for Molshil Oral Thin Films after sufficiently complying bioequivalence requirements

    Read More
  • Shilpa Medicare’s finished dosage formulation facility gets GMP certification from Russian Federation
    28th May 2021, 16:29 PM

    There were No Critical, Major and Minor observations found during GMP inspection process

    Read More
  • Shilpa Medicare’s arm ties up with Dr. Reddy's for production of Sputnik V vaccine
    17th May 2021, 10:16 AM

    DRL has partnered with HVIRDIF for clinical development of the vaccine and has distribution rights in geographies including India

    Read More
  • Shilpa Medicare’s US operating company sues Novartis Pharmaceutical Corporation
    27th Apr 2021, 09:12 AM

    The company is seeking relief for the infringement of the US Patent entitled ‘Fingolimod Polymorph and Their Processes’

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.